Based on the Anavex Life Sciences Corp stock forecast from 2 analysts, the average analyst target price for Anavex Life Sciences Corp is USD 28.50 over the next 12 months. Anavex Life Sciences Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Anavex Life Sciences Corp is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Anavex Life Sciences Corp’s stock price was USD 9.42. Anavex Life Sciences Corp’s stock price has changed by +5.25% over the past week, -1.26% over the past month and +173.84% over the last year.
No recent analyst target price found for Anavex Life Sciences Corp
No recent average analyst rating found for Anavex Life Sciences Corp
Company Overview Anavex Life Sciences Corp
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. The company's lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. It also provides ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York. Read Less
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. The company's lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disea...Read More
Frequently Asked Questions About Anavex Life Sciences Corp (AVXL) Stock
Based on ratings from 2 analysts Anavex Life Sciences Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on AVXL's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for AVXL is USD 28.50 over the next 12 months. The maximum analyst target price is USD 42 while the minimum anlayst target price is USD 15.
Unfortunately we do not have enough data on AVXL's stock to indicate if its overvalued.
The last closing price of AVXL's stock was USD 9.42.
The most recent market capitalization for AVXL is USD 0.80B.
Based on targets from 2 analysts, the average taret price for AVXL is projected at USD 28.50 over the next 12 months.
This means that AVXL's stock price may go up by +202.55% over the next 12 months.
We can't find any ETFs which contains Anavex Life Sciences Corp's stock.
As per our most recent records Anavex Life Sciences Corp has 42 Employees.
Anavex Life Sciences Corp's registered address is 630 5th Avenue, New York, NY, United States, 10111.
You can get more information about it from Anavex Life Sciences Corp's website at https://www.anavex.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Anavex Life Sciences Corp (AVXL) Stock
Based on ratings from 2 analysts Anavex Life Sciences Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on AVXL's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for AVXL is USD 28.50 over the next 12 months. The maximum analyst target price is USD 42 while the minimum anlayst target price is USD 15.
Unfortunately we do not have enough data on AVXL's stock to indicate if its overvalued.
The last closing price of AVXL's stock was USD 9.42.
The most recent market capitalization for AVXL is USD 0.80B.
Based on targets from 2 analysts, the average taret price for AVXL is projected at USD 28.50 over the next 12 months.
This means that AVXL's stock price may go up by +202.55% over the next 12 months.
We can't find any ETFs which contains Anavex Life Sciences Corp's stock.
As per our most recent records Anavex Life Sciences Corp has 42 Employees.
Anavex Life Sciences Corp's registered address is 630 5th Avenue, New York, NY, United States, 10111.
You can get more information about it from Anavex Life Sciences Corp's website at https://www.anavex.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AVXL !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
